The need for improved AD therapeutics is considerable; current treatment options are limited, and none can cease or even delay the inexorable cognitive and functional decline caused by the disease. Mild to moderate AD is a key area of focus and commercial opportunity for the pharmaceutical industry: early-stage AD patients are the prime targets for disease-modifying interventions—the Holy Grail in AD drug development—and are also candidates for improved symptomatic options, which hinge on maximizing the function of existing neurons. New entrants that can safely deliver therapeutic gains over current mainstays are sought after by physicians, patients and their families, and healthcare systems that face a rapidly expanding AD population.

Table of contents

  • Alzheimer's Disease - Unmet Need - Detailed, Expanded Analysis: Mild To Moderate Alzheimer's Disease
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in Mild to Moderate Alzheimer's Disease
        • Importance of Efficacy Attributes to Prescribing Decisions in Mild to Moderate Alzheimer's Disease — United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Mild to Moderate Alzheimer's Disease — Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Mild to Moderate Alzheimer's Disease — United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Mild to Moderate Alzheimer's Disease — Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Mild to Moderate Alzheimer's Disease — United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Mild to Moderate Alzheimer's Disease — Europe
        • Importance of Non-Clinical Factors to Prescribing Decisions in Mild to Moderate Alzheimer's Disease — United States
        • Importance of Non-Clinical Factors to Prescribing Decisions in Mild to Moderate Alzheimer's Disease — Europe
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration and Non-Clinical Attributes to Prescribing Decisions in Mild to Moderate Alzheimer's Disease — United States
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration and Non-Clinical Attributes to Prescribing Decisions in Mild to Moderate Alzheimer's Disease — Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Product and Regimens for Mild to Moderate Alzheimer's Disease
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for Mild to Moderate Alzheimer's Disease — United States
        • Overall Performance of Key Therapies for Alzheimer's Disease — Europe
        • Relative Performance of Key Therapies for Mild to Moderate Alzheimer's Disease Across Select Efficacy Attributes — United States
        • Relative Performance of Key Therapies for Alzheimer's Disease Across Select Efficacy Attributes — Europe
        • Relative Performance of Key Therapies for Mild to Moderate Alzheimer's Disease Across Select Safety and Tolerability Attributes — United States
        • Relative Performance of Key Therapies for Mild to Moderate Alzheimer's Disease Across Select Safety and Tolerability Attributes — Europe
        • Relative Performance of Key Therapies for Mild to Moderate Alzheimer's Disease Across Select Convenience of Administration Attributes — United States
        • Relative Performance of Key Therapies for Mild to Moderate Alzheimer's Disease Across Select Convenience of Administration Attributes — Europe
        • Relative Performance of Key Therapies for Mild to Moderate Alzheimer's Disease Across Select Non-Clinical Attributes — United States
        • Relative Performance of Key Therapies for Mild to Moderate Alzheimer's Disease Across Select Non-Clinical Attributes — Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Neurologists' Satisfaction with the Performance of Key Therapies for Mild to Moderate Alzheimer's Disease on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — United States
        • Surveyed Neurologists' Satisfaction with the Performance of Key Therapies for Mild to Moderate Alzheimer's Disease on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — Europe
      • Physician Rating of Unmet Need in Mild to Moderate Alzheimer's Disease
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Mild to Moderate Alzheimer's Disease — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Mild to Moderate Alzheimer's Disease — Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Mild to Moderate Alzheimer's Disease — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Mild to Moderate Alzheimer's Disease — Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Mild to Moderate Alzheimer's Disease — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Mild to Moderate Alzheimer's Disease — Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Non-clinical Factors in Mild to Moderate Alzheimer's Disease — United States
        • Surveyed Neurologist Ascribed Level of Unmet Need Across Key Non-clinical Factors in Mild to Moderate Alzheimer's Disease — Europe
      • Unmet Need in Alzheimer's Disease and Related Indications
        • Surveyed Neurologists' Ascribed Level of Unmet Need in Alzheimer's Disease and Related Indications — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need in Alzheimer's Disease and Related Indications — Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Mild to Moderate Alzheimer's Disease Market and Emerging Therapy Insights
        • Opportunity: A Disease-Modifying Therapy
        • Opportunity: A Novel Procognitive Therapy to Improve the Symptomatic Treatment of Mild to Moderate Alzheimer's Disease
        • Opportunity: A Symptomatic Therapy to Treat the Behavioral Symptoms of Alzheimer's Disease
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • Early Alzheimer's Disease Target Product Profile Analysis: Attribute Importance
        • Early Alzheimer's Disease Target Product Profile Analysis: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Early Alzheimer's Disease Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • Early Alzheimer's Disease Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • Early Alzheimer's Disease Market Simulations: Target Product Profiles Included in Scenario 1
        • Early Alzheimer's Disease Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • Early Alzheimer's Disease Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • Early Alzheimer's Disease Market Simulations: Target Product Profiles Included in Scenario 2

Author(s): Tamara Blutstein, PhD

Tamara Blutstein is a Senior Business Insights Analyst on the Central Nervous System, Pain, and Ophthalmology team. She is responsible for analyzing and forecasting pharmaceutical markets, primarily in Neurology indications, with specific expertise in Alzheimer’s disease, Parkinson’s disease, and ischemic stroke.

Prior to joining the company, Tamara was a postdoctoral fellow at Tufts University School of Medicine, where she studied the role of gliotransmission in the regulation of sleep and sleep homeostasis. She earned a Ph.D. in neuroscience from the University of Maryland School of Medicine where she conducted research on the role of gonadal hormones in modulating neuronal-glial communication. She holds a B.A. in neuroscience from Drew University.


Related Reports

Alzheimer's Disease - Landscape & Forecast - Disease Landscape & Forecast

View Details

Alzheimer's Disease | Disease Landscape and Forecast | G7 | 2020

The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives—i...

View Details

Alzheimer's Disease - Epidemiology - Mature Markets

DRG Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key...

View Details